 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SOLANA BEACH, Calif., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...

Artelo Biosciences to Present at the 13th Congress of the European Pain Federation on September 20th

SOLANA BEACH, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...

Artelo Biosciences to Present at the 6th Cannabinoid-Derived Drug Development Summit on September 12th

SOLANA BEACH, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...

Artelo Biosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference on September 13th

Artelo Q2 Net Loss Declines 33% YoY, Here Is What You Need To Know

New data demonstrates that ART26.12 works by activating multiple receptors implicated in pain signaling and is able to broadly modify lipids in chemotherapy-induced peripheral neuropathySOLANA BEACH...

Artelo Biosciences to Present New Mechanism of Action Data on ART26.12 at the Gordon Research Conference on July 20, 2023

SOLANA BEACH, Calif., July 10, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc.(Nasdaq:ARTL),a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced that Gregory D...

Artelo Biosciences CEO to Participate in the Benzinga All Access Event on July 11

Former Awardee and Artelo Employee, Professor Saoirse OSullivan will Present the 2023 Recipient with the AwardSOLANA BEACH, Calif., June 28, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc.(Nasdaq:ARTL),a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to ...

Artelo Biosciences Announces Sponsorship of The William A. Devane Early Career Investigator Award at the 33rd Annual International Cannabinoid Research Society Symposium

In a report released today, Michael Higgins from Ladenburg ThalmannCo. maintained a Buy rating on Artelo Biosciences (ARTL Research Report), w... In a report released today, Michael Higgins from Ladenburg Thalmann  Co. maintained a Buy rating on Artelo Biosciences (ARTL &#8211...

Artelo Biosciences (ARTL) Receives a Buy from Ladenburg Thalmann & Co.

ART26.12, a Novel Fatty Acid Binding Protein 5 (FABP5) Inhibitor, Shows Favorable Results in Studies for Chemotherapy-Induced Neuropathy and Diabetic Neuropathy ART26.12 targeting global neuropathic pain market valued at $7.6 billion in 2023 Anticipates FDA pre-IND meeting minutes during the third ...

Artelo Biosciences Announces Important New Data on ART26.12 Demonstrating Positive Effects in Multiple Models of Neuropathic Pain at the 33rd Annual International Cannabinoid Research Society Symposium

Artelo Biosciences Presents Groundbreaking Research At Annual CBD Symposium In Canada

Artelo Biosciences, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system. Its product candidate pipeline includes ART27.13-Synthetic Cannabinoid Agonist, ART26.12-FABP5 inhibitor, and ART12.11-Synthetic CBD Cocrystal. The company was founded on May 2, 2011 and is headquartered in Solana Beach, CA.

Watchers	10,345
52-Wk Low	$1.39
52-Wk High	$3.69

Market Cap	$4.44M
Volume (M)	22,583.00
52-Wk High	$3.69
52-Wk Low	$1.39

ARTL Artelo Biosciences Inc

About

Feed

News

Fundamentals